Immunogenicity and safety of fractional doses of Sanofi Pasteur's inactivated poliomyelitis vaccine administered intradermally vs full doses of inactivated poliomyelitis vaccine administered intramuscularly in healthy Philippines infants

Next Previous
Trial Profile

Immunogenicity and safety of fractional doses of Sanofi Pasteur's inactivated poliomyelitis vaccine administered intradermally vs full doses of inactivated poliomyelitis vaccine administered intramuscularly in healthy Philippines infants

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2014

At a glance

  • Drugs Poliovirus vaccine inactivated (Primary)
  • Indications Poliomyelitis
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur

    • Most Recent Events

    • 01 Feb 2012 Results published in the International Journal of Infectious Diseases.
    • 24 Mar 2010 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top